Quantitative proteomic and interaction network analysis of cisplatin resistance in HeLa cells

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Chavez, Juan D ^a   Hoopmann, Michael R ^a   Weisbrod, Chad R ^a   Takara, Kohji ^b   Bruce, James E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b HIMEJI DOKKYO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE PHOSPHORIBOSYLTRANSFERASE; ALDEHYDE REDUCTASE; AMINO ACID; CALCIUM REGLATED HEAT STABLE PROTEIN 1; CATHEPSIN D; CELL PROTEIN; CISPLATIN; DR1 ASSOCIATED COREPRESSOR; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GUANINE NUCLEOTIDE BINDING PROTEIN G(K) SUBUNIT ALPHA; GUANINE NUCLEOTIDE BINDING PROTEIN SUBUNIT GAMMA 12; HEAT SHOCK PROTEIN BETA 11; HISTONE H1.2; HLA ANTIGEN CLASS 1 CEW 5 ALPHA CHAIN; ISOCITRATE DEHYDROGENASE (NADP); PHOSPHOGLUCOMUTASE; PLASMINOGEN ACTIVATOR INHIBITOR 1 RNA BINDING PROTEIN; PROTEIN EBP2; PROTEIN S100 A4; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE) 1; RIBOSOMAL BIOGENESIS PROTEIN BRX1 HOMOLOG; RIBOSOMAL L1 DOMAIN CONTAINING PROTEIN 1; SYNAPTIC VESICLE MEMBRANE PROTEIN VAT 1 HOMOLOG; UNCLASSIFIED DRUG; TUMOR PROTEIN;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; HELA CELL; HUMAN; HUMAN CELL; ISOTOPE LABELING; MASS SPECTROMETRY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; DRUG EFFECT; METABOLISM; METHODOLOGY; PROTEIN BINDING; WESTERN BLOTTING;

BLOTTING, WESTERN; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HELA CELLS; HUMANS; NEOPLASM PROTEINS; PROTEIN BINDING; PROTEOMICS; SIGNAL TRANSDUCTION;

EID: 79957561774     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019892     Document Type: Article

References (57)

1. Siddik ZH, (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279.
2. Kartalou M, Essigmann JM, (2001) Mechanisms of resistance to cisplatin. Mutation research 478: 23-43.
3. Kelland L, (2007) The resurgence of platinum-based cancer chemotherapy. Nature reviews Cancer 7: 573-584.
4. Wu HI, Brown JA, Dorie MJ, Lazzeroni L, Brown JM, (2004) Genome-wide identification of genes conferring resistance to the anticancer agents cisplatin, oxaliplatin, and mitomycin C. Cancer research 64: 3940-3948.
5. Toshimitsu H, Hashimoto K, Tangoku A, Iizuka N, Yamamoto K, et al. (2004) Molecular signature linked to acquired resistance to cisplatin in esophageal cancer cells. Cancer letters 211: 69-78.
6. Anderson L, Seilhamer J, (1997) A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18: 533-537.
7. Greenbaum D, Colangelo C, Williams K, Gerstein M, (2003) Comparing protein abundance and mRNA expression levels on a genomic scale. Genome biology 4: 117.
8. Gygi SP, Rochon Y, Franza BR, Aebersold R, (1999) Correlation between protein and mRNA abundance in yeast. Molecular and cellular biology 19: 1720-1730.
9. Stewart JJ, White JT, Yan X, Collins S, Drescher CW, et al. (2006) Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Molecular & cellular proteomics: MCP 5: 433-443.
10. Zhang JT, Liu Y, (2007) Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment. Cancer treatment reviews 33: 741-756.
11. Vidal M, Cusick ME, Barabasi AL, Interactome networks and human disease. Cell 144: 986-998.
12. Araujo RP, Liotta LA, Petricoin EF, (2007) Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nature reviews Drug discovery 6: 871-880.
13. Takara K, Obata Y, Yoshikawa E, Kitada N, Sakaeda T, et al. (2006) Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel. Cancer chemotherapy and pharmacology 58: 785-793.
14. Maere S, Heymans K, Kuiper M, (2005) BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics (Oxford, England) 21: 3448-3449.
15. Gatenby RA, Gillies RJ, (2007) Glycolysis in cancer: a potential target for therapy. The international journal of biochemistry & cell biology 39: 1358-1366.
16. Tredan O, Galmarini CM, Patel K, Tannock IF, (2007) Drug resistance and the solid tumor microenvironment. Journal of the National Cancer Institute 99: 1441-1454.
17. Rohwer N, Dame C, Haugstetter A, Wiedenmann B, Detjen K, et al. Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. PloS one 5: e12038.
18. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, et al. (2005) Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer research 65: 613-621.
19. Lee EK, Regenold WT, Shapiro P, (2002) Inhibition of aldose reductase enhances HeLa cell sensitivity to chemotherapeutic drugs and involves activation of extracellular signal-regulated kinases. Anti-cancer drugs 13: 859-868.
20. Saraswat M, Mrudula T, Kumar PU, Suneetha A, Rao Rao TS, et al. (2006) Overexpression of aldose reductase in human cancer tissues. Medical science monitor: international medical journal of experimental and clinical research 12: CR525-529.
21. Berndtsson M, Hagg M, Panaretakis T, Havelka AM, Shoshan MC, et al. (2007) Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. International journal of cancer Journal international du cancer 120: 175-180.
22. Yao X, Panichpisal K, Kurtzman N, Nugent K, (2007) Cisplatin nephrotoxicity: a review. The American journal of the medical sciences 334: 115-124.
23. Townsend DM, Tew KD, (2003) The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22: 7369-7375.
24. Piaggi S, Raggi C, Corti A, Pitzalis E, Mascherpa MC, et al. (2010) Glutathione transferase omega 1-1 (GSTO1-1) plays an anti-apoptotic role in cell resistance to cisplatin toxicity. Carcinogenesis 31: 804-811.
25. Chung YM, Yoo YD, Park JK, Kim YT, Kim HJ, (2001) Increased expression of peroxiredoxin II confers resistance to cisplatin. Anticancer research 21: 1129-1133.
26. Pak JH, Choi WH, Lee HM, Joo WD, Kim JH, et al. Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells. Cancer investigation 29: 21-28.
27. Kim RH, Peters M, Jang Y, Shi W, Pintilie M, et al. (2005) DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer cell 7: 263-273.
28. Fan J, Ren H, Jia N, Fei E, Zhou T, et al. (2008) DJ-1 decreases Bax expression through repressing p53 transcriptional activity. The Journal of biological chemistry 283: 4022-4030.
29. Toole BP, Slomiany MG, (2008) Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Seminars in cancer biology 18: 244-250.
30. Wang SJ, Bourguignon LY, (2006) Hyaluronan-CD44 promotes phospholipase C-mediated Ca2+ signaling and cisplatin resistance in head and neck cancer. Archives of otolaryngology-head & neck surgery 132: 19-24.
31. Misra S, Ghatak S, Toole BP, (2005) Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. The Journal of biological chemistry 280: 20310-20315.
32. Xu Y, Stamenkovic I, Yu Q, CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer research 70: 2455-2464.
33. Martin TA, Harrison G, Mansel RE, Jiang WG, (2003) The role of the CD44/ezrin complex in cancer metastasis. Critical reviews in oncology/hematology 46: 165-186.
34. Salama I, Malone PS, Mihaimeed F, Jones JL, (2008) A review of the S100 proteins in cancer. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 34: 357-364.
35. Semov A, Moreno MJ, Onichtchenko A, Abulrob A, Ball M, et al. (2005) Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmin formation. The Journal of biological chemistry 280: 20833-20841.
36. Grigorian M, Andresen S, Tulchinsky E, Kriajevska M, Carlberg C, et al. (2001) Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction. The Journal of biological chemistry 276: 22699-22708.
37. Mahon PC, Baril P, Bhakta V, Chelala C, Caulee K, et al. (2007) S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer research 67: 6786-6795.
38. Mencia N, Selga E, Rico I, de Almagro MC, Villalobos X, et al. (2010) Overexpression of S100A4 in human cancer cell lines resistant to methotrexate. BMC cancer 10: 250.
39. Benes P, Vetvicka V, Fusek M, (2008) Cathepsin D-many functions of one aspartic protease. Critical reviews in oncology/hematology 68: 12-28.
40. Sopkova-de Oliveira Santos J, Oling FK, Rety S, Brisson A, Smith JC, et al. (2000) S100 protein-annexin interactions: a model of the (Anx2-p11)(2) heterotetramer complex. Biochimica et biophysica acta 1498: 181-191.
41. Han EK, Tahir SK, Cherian SP, Collins N, Ng SC, (2000) Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. British journal of cancer 83: 83-88.
42. Florczyk U, Golda S, Zieba A, Cisowski J, Jozkowicz A, et al. (2011) Overexpression of biliverdin reductase enhances resistance to chemotherapeutics. Cancer letters 300: 40-47.
43. Nomura M, Matsunami T, Kobayashi K, Uchibayashi T, Koshida K, et al. (2005) Involvement of ABC transporters in chemosensitivity of human renal cell carcinoma, and regulation of MRP2 expression by conjugated bilirubin. Anticancer research 25: 2729-2735.
44. Leung-Pineda V, Huh J, Piwnica-Worms H, (2009) DDB1 targets Chk1 to the Cul4 E3 ligase complex in normal cycling cells and in cells experiencing replication stress. Cancer research 69: 2630-2637.
45. Holcomb VB, Rodier F, Choi Y, Busuttil RA, Vogel H, et al. (2008) Ku80 deletion suppresses spontaneous tumors and induces a p53-mediated DNA damage response. Cancer research 68: 9497-9502.
46. Yang J, Yu Y, Hamrick HE, Duerksen-Hughes PJ, (2003) ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses. Carcinogenesis 24: 1571-1580.
47. Woo RA, McLure KG, Lees-Miller SP, Rancourt DE, Lee PW, (1998) DNA-dependent protein kinase acts upstream of p53 in response to DNA damage. Nature 394: 700-704.
48. Jordan P, Carmo-Fonseca M, (1998) Cisplatin inhibits synthesis of ribosomal RNA in vivo. Nucleic acids research 26: 2831-2836.
49. Rosenberg JM, Sato PH, (1993) Cisplatin inhibits in vitro translation by preventing the formation of complete initiation complex. Molecular pharmacology 43: 491-497.
50. Warner JR, McIntosh KB, (2009) How common are extraribosomal functions of ribosomal proteins? Molecular cell 34: 3-11.
51. Deutsch EW, Mendoza L, Shteynberg D, Farrah T, Lam H, et al. A guided tour of the Trans-Proteomic Pipeline. Proteomics 10: 1150-1159.
52. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS, (1999) Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20: 3551-3567.
53. Hoopmann MR, Finney GL, MacCoss MJ, (2007) High-speed data reduction, feature detection, and MS/MS spectrum quality assessment of shotgun proteomics data sets using high-resolution mass spectrometry. Analytical chemistry 79: 5620-5632.
54. Cox J, Mann M, (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nature biotechnology 26: 1367-1372.
55. Eisen MB, Spellman PT, Brown PO, Botstein D, (1998) Cluster analysis and display of genome-wide expression patterns. Proceedings of the National Academy of Sciences of the United States of America 95: 14863-14868.
56. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, et al. (2009) STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic acids research 37: D412-416.
57. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research 13: 2498-2504.